$SFES
SAFEGUARD SCIENTIFICS INC Stock $sfes

$sfes Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000143774922006038 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	-$65.00K	$1.564M	$1.700M
YoY Change	-105.42%	-25.52%	-5.56%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	-$65.00K	$1.564M	$1.700M
YoY Change	-105.42%	-25.52%	-5.56%
Operating Profit	-$1.135M	-$1.564M	-$2.463M
YoY Change	-30.41%	-31.25%	-30.27%
Interest Expense	-$1.507M	-$691.0K	$19.40M
YoY Change	-49.77%	-42.42%	-818.52%
% of Operating Profit
Other Income/Expense, Net	-$5.992M	$20.59M	$706.0K
YoY Change	803.77%	-2610.73%	-119.79%
Pretax Income	-$8.634M	$18.33M	$17.63M
YoY Change	17.42%	-522.13%	-210.1%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%	0.0%
Net Earnings	-$8.634M	$18.33M	$17.63M
YoY Change	17.42%	-522.13%	-210.1%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.51	$0.88	$0.84
Diluted Earnings Per Share	-$0.51	$0.88	$0.84
COMMON SHARES
Basic Shares Outstanding	16.51M	20.79M	20.90M
Diluted Shares Outstanding		20.79M	20.93M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.74M	$64.21M	$21.80M
YoY Change	58.58%	291.53%	4.31%
Cash & Equivalents	$24.74M	$64.20M	$21.80M
Short-Term Investments	$4.549M	$10.80M
Other Short-Term Assets	$5.539M	$12.16M	$600.0K
YoY Change	1007.8%	1926.67%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$30.28M	$76.37M	$22.36M
YoY Change	88.5%	349.06%	3.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.561M	$1.622M	$1.736M
YoY Change	-12.79%	-13.22%	-14.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$21.21M	$23.95M	$27.81M
YoY Change	-23.77%	-22.02%	-5.91%
Other Assets	$217.0K	$233.0K	$292.0K
YoY Change	-72.32%	-82.97%	-85.34%
Total Long-Term Assets	$23.75M	$27.35M	$64.62M
YoY Change	-55.16%	-53.71%	-8.75%
TOTAL ASSETS
Total Short-Term Assets	$30.28M	$76.37M	$22.36M
Total Long-Term Assets	$23.75M	$27.35M	$64.62M
Total Assets	$54.03M	$103.7M	$86.98M
YoY Change	-21.74%	36.31%	-5.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$41.00K	$77.00K	$18.00K
YoY Change	-26.79%	113.89%	-87.23%
Accrued Expenses	$524.0K	$643.0K	$577.0K
YoY Change	27.8%	21.09%	1.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.734M	$3.899M	$3.978M
YoY Change	-50.03%	49.33%	24.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$50.00K	$50.00K	$50.00K
YoY Change	-92.15%	-95.49%	-95.5%
Total Long-Term Liabilities	$50.00K	$50.00K	$50.00K
YoY Change	-92.15%	-95.49%	-95.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.734M	$3.899M	$3.978M
Total Long-Term Liabilities	$50.00K	$50.00K	$50.00K
Total Liabilities	$3.462M	$5.725M	$5.992M
YoY Change	-43.8%	-2.29%	-9.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$709.6M	-$701.0M	-$719.0M
YoY Change	-3.67%	-3.88%	0.81%
Common Stock	$808.8M	$808.7M	$809.3M
YoY Change	-0.12%	-0.33%	-0.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$48.57M	$9.688M	$9.237M
YoY Change	376.17%	-17.94%	-33.64%
Treasury Stock Shares	$5.068M	$777.0K	$630.0K
Shareholders Equity	$50.57M	$97.99M	$81.00M
YoY Change
Total Liabilities & Shareholders Equity	$54.03M	$103.7M	$86.98M
YoY Change	-21.74%	36.31%	-5.87%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q1
OPERATING ACTIVITIES
Net Income	-$8.634M	$18.33M	$17.63M
YoY Change	17.42%	-522.13%	-210.1%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.708M	-$710.0K	-$2.157M
YoY Change	146.18%	-40.83%	-15.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$2.273M	$43.69M	$8.400M
YoY Change	657.67%	992.25%	-660.0%
Cash From Investing Activities	$2.273M	$43.69M	$8.419M
YoY Change	657.67%	992.25%	-649.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-39.04M	-74.00K	-$88.00K
YoY Change			700.0%
NET CHANGE
Cash From Operating Activities	-2.708M	-710.0K	-$2.157M
Cash From Investing Activities	2.273M	43.69M	$8.419M
Cash From Financing Activities	-39.04M	-74.00K	-$88.00K
Net Change In Cash	-39.47M	42.91M	$6.174M
YoY Change	4834.0%	1432.36%	-250.77%
FREE CASH FLOW
Cash From Operating Activities	-$2.708M	-$710.0K	-$2.157M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	83333000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	83333000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21573000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21573000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21573000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21573000
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5068000
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	688000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
CY2021Q4	sfe	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Award Vesting Types SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAwardVestingTypes	2	pure
CY2020Q4	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0.0	USD
CY2020	sfe	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Negative Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNegativeRatePercent	-0.210	pure
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24739000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15601000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2021Q4	us-gaap	Trading Securities TradingSecurities	4549000	USD
CY2020Q4	us-gaap	Trading Securities TradingSecurities	0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	965000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	462000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	30278000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	16063000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1561000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1790000	USD
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	21972000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	50398000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	217000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	784000	USD
CY2021Q4	us-gaap	Assets Assets	54028000	USD
CY2020Q4	us-gaap	Assets Assets	69035000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	41000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	56000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	794000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2677000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	524000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	410000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	327000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1734000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3470000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	50000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	637000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1678000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2053000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	3462000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	6160000	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2157000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2157000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	806638000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	807582000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	48569000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	10200000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-709635000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-736639000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50566000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	62875000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54028000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	69035000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7153000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9466000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-7153000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-9466000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22035000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7708000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	276000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	261000	USD
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	11846000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-20702000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	27004000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37615000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	27004000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-37615000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.36
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.36
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19827000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20751000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19827000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20751000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	101741000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-37615000	USD
CY2020	sfe	Stock Issued During Period Value Restricted Stock Award Withheld For Taxes StockIssuedDuringPeriodValueRestrictedStockAwardWithheldForTaxes	40000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	590000	USD
CY2020	sfe	Cumulative Effect Of Change In Accounting At Ownership Interests CumulativeEffectOfChangeInAccountingAtOwnershipInterests	1801000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	62875000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	27004000	USD
CY2021	sfe	Stock Issued During Period Value Restricted Stock Award Withheld For Taxes StockIssuedDuringPeriodValueRestrictedStockAwardWithheldForTaxes	-736000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	606000	USD
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	40655000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50566000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	27004000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-37615000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	229000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	311000	USD
CY2021	sfe	Income Loss From Equity Method Investments Excluding Impairments IncomeLossFromEquityMethodInvestmentsExcludingImpairments	11846000	USD
CY2020	sfe	Income Loss From Equity Method Investments Excluding Impairments IncomeLossFromEquityMethodInvestmentsExcludingImpairments	-9420000	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-2521000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-20039000	USD
CY2021	sfe	Gain Loss From Observable Price Changes GainLossFromObservablePriceChanges	8505000	USD
CY2020	sfe	Gain Loss From Observable Price Changes GainLossFromObservablePriceChanges	1224000	USD
CY2021	sfe	Gain From Sale Of Ownership Interests GainFromSaleOfOwnershipInterests	35284000	USD
CY2020	sfe	Gain From Sale Of Ownership Interests GainFromSaleOfOwnershipInterests	-0	USD
CY2021	sfe	Increase Decrease In Fair Value Of Ownership Interests IncreaseDecreaseInFairValueOfOwnershipInterests	-19255000	USD
CY2020	sfe	Increase Decrease In Fair Value Of Ownership Interests IncreaseDecreaseInFairValueOfOwnershipInterests	-0	USD
CY2021	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	22000	USD
CY2020	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-175000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1779000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	965000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	238000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	137000	USD
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-3045000	USD
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-77000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8152000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8143000	USD
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	-0	USD
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	7534000	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	60832000	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	7903000	USD
CY2021	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	2718000	USD
CY2020	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	1638000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58114000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1269000	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	40655000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	144000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	40000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-40799000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-40000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9163000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9452000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15601000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25053000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24764000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15601000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24700000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.041	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.243	pure
CY2021Q1	us-gaap	Profit Loss ProfitLoss	17625000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-320000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	18333000	USD
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-8634000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.84
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Accounting Estimates</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results <em style="font: inherit;"> may </em>differ from these estimates. These estimates include the evaluation of the recoverability of the Company’s ownership interests and advances, the recoverability of deferred tax assets, stock-based compensation and commitments and contingencies. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and <em style="font: inherit;"> may </em>require adjustments in the future when audits of these entities’ financial statements are completed.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At <em style="font: inherit;"> December 31, 2021</em>, the Company believes the carrying value of the Company’s ownership interests and advances is <em style="font: inherit;">not</em> impaired, although there can be <em style="font: inherit;">no</em> assurance that the Company’s future results will confirm this assessment, that a significant write-down or write-off will <em style="font: inherit;">not</em> be required in the future or that a significant loss will <em style="font: inherit;">not</em> be recorded in the future upon the sale of a company.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24739000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15601000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	25000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24764000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15601000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.169	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.36
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.84
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12	pure
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
CY2019Q2	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P18M
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	601000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	540000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	607000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	556000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	613000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	573000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	619000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	590000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	207000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	199000	USD
CY2021Q4	sfe	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	0	USD
CY2021Q4	sfe	Lessor Operating Lease Payments To Be Received Six Years LessorOperatingLeasePaymentsToBeReceivedSixYears	0	USD
CY2021Q4	sfe	Lessee Operating Lease Liability To Be Paid After Year Six LesseeOperatingLeaseLiabilityToBePaidAfterYearSix	0	USD
CY2021Q4	sfe	Lessor Operating Lease Payment To Be Received After Year Six LessorOperatingLeasePaymentToBeReceivedAfterYearSix	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2647000	USD
CY2021Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2458000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	595000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2052000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-37615000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19827000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20751000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.36
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	21208000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	27821000	USD
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5313000	USD
CY2020Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	19951000	USD
CY2021Q4	us-gaap	Advances To Affiliate AdvancesToAffiliate	0	USD
CY2020Q4	us-gaap	Advances To Affiliate AdvancesToAffiliate	2626000	USD
CY2021Q4	sfe	Investments And Advances To Affiliates Current And Noncurrent InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent	26521000	USD
CY2020Q4	sfe	Investments And Advances To Affiliates Current And Noncurrent InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent	50398000	USD
CY2021	sfe	Impairment Of Other Method Securities ImpairmentOfOtherMethodSecurities	2500000	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-300000	USD
CY2021Q4	sfe	Equity Method Investment Assets Exceed Carrying Value Of Investment EquityMethodInvestmentAssetsExceedCarryingValueOfInvestment	11400000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	27004000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-37615000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19827000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20751000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1779000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	965000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05	pure
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0.0	USD
CY2021	sfe	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Negative Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNegativeRatePercent	0.210	pure
CY2021	sfe	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Negative Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNegativeRatePercent	0.210	pure
CY2020	sfe	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Negative Rate Percent EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNegativeRatePercent	-0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.033	pure
CY2021Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	31985000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	38361000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	77045000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	76023000	USD
CY2021Q4	sfe	Deferred Tax Asset Disallowed Interest Carryforwards DeferredTaxAssetDisallowedInterestCarryforwards	7120000	USD
CY2020Q4	sfe	Deferred Tax Asset Disallowed Interest Carryforwards DeferredTaxAssetDisallowedInterestCarryforwards	7292000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	24000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	497000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	268000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	302000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	136000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	482000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	116578000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	122957000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116578000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	122957000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	367000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	52000000	USD
CY2021Q4	sfe	Net Operating Loss Carryforwards Expiring In Year One NetOperatingLossCarryforwardsExpiringInYearOne	47137000	USD
CY2021Q4	sfe	Net Operating Loss Carryforwards Expiring In Year Two NetOperatingLossCarryforwardsExpiringInYearTwo	47150000	USD
CY2021Q4	sfe	Net Operating Loss Carryforwards Expiring In Year Three NetOperatingLossCarryforwardsExpiringInYearThree	50140000	USD
CY2021Q4	sfe	Net Operating Loss Carryforwards Expiring In Year Four NetOperatingLossCarryforwardsExpiringInYearFour	17266000	USD
CY2021Q4	sfe	Net Operating Loss Carryforwards Expiring In Year Five And Thereafter NetOperatingLossCarryforwardsExpiringInYearFiveAndThereafter	152923000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	314616000	USD
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2021	us-gaap	Profit Loss ProfitLoss	27004000	USD
CY2021	sfe	Long Term Incentive Plan Payments LongTermIncentivePlanPayments	2500000	USD
CY2021Q4	us-gaap	Deferred Compensation Liability Current And Noncurrent DeferredCompensationLiabilityCurrentAndNoncurrent	0	USD
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1000000.0	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6800000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2463000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1991000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1564000	USD
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1135000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2463000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1991000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1564000	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1135000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	706000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6733000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20588000	USD
CY2021Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5992000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	53000	USD
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	74000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	70000	USD
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	79000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	19329000	USD
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5136000	USD
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-761000	USD
CY2021Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1586000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17625000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-320000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18333000	USD
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8634000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.88
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3532000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2028000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2275000	USD
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1631000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3532000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2028000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2275000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1631000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3567000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2658000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-820000	USD
CY2020Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-663000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	105000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	52000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	52000	USD
CY2020Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	52000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9014000	USD
CY2020Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5277000	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1300000	USD
CY2020Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5111000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16008000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9911000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4343000	USD
CY2020Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7353000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-16008000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-9911000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-4343000	USD
CY2020Q4	us-gaap	Profit Loss ProfitLoss	-7353000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35

Files In Submission

Name	View Source	Status
0001437749-22-006038-index-headers.html	Edgar Link	pending
0001437749-22-006038-index.html	Edgar Link	pending
0001437749-22-006038.txt	Edgar Link	pending
0001437749-22-006038-xbrl.zip	Edgar Link	pending
a01.jpg	Edgar Link	pending
ex_311221.htm	Edgar Link	pending
ex_311222.htm	Edgar Link	pending
ex_311223.htm	Edgar Link	pending
ex_311224.htm	Edgar Link	pending
ex_311225.htm	Edgar Link	pending
ex_311226.htm	Edgar Link	pending
ex_311227.htm	Edgar Link	pending
ex_311228.htm	Edgar Link	pending
ex_337363.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sfe-20211231.xsd	Edgar Link	pending
sfe-20211231_cal.xml	Edgar Link	unprocessable
sfe-20211231_def.xml	Edgar Link	unprocessable
sfe-20211231_lab.xml	Edgar Link	unprocessable
sfe-20211231_pre.xml	Edgar Link	unprocessable
sfe20211231_10k.htm	Edgar Link	pending
sfe20211231_10k_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SFES
SAFEGUARD SCIENTIFICS INC Stock $sfes

2021 Q4 Form 10-K Financial Statement

#000143774922006038 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SFES SAFEGUARD SCIENTIFICS INC Stock $sfes

2021 Q4 Form 10-K Financial Statement

#000143774922006038 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SFES
SAFEGUARD SCIENTIFICS INC Stock $sfes